Coherus Biosciences

Cimerli

Manufacturer:

Coherus Biosciences

Cimerli HCPCS:

Q5128

HCPCS Code Descriptor:

Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg

Category:

Q Code

Cimerli NDCs:

70114-0441-01, 70114-0440-01

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Cimerli:

Cimerli is an Opthalmic drug manufactured by Coherus Biosciences and administered via the Intraocular route of administration. The Q Code: Q5128 is aligned to the drug Cimerli.

Cimerli can be used to treat eye conditions that involve blood vessel growth under the retina and macula of the eye. Cimerli slows the growth and prevents leakage of abnormal blood vessels that grow in the eye. This medication is manufactured by Coherus Biosciences and is a biosimilar to the medication Lucentis (J2778). Cimerli is aligned to the HCPCS code Q5128, this HCPCS code was aligned to the medication in April 2023. Patient assistance programs for Cimerli can be found through Cimerla Solutions.

ACCESS PRICING AND MORE BY REGISTERING

Q5128 Added Date:

April 1, 2023

Q5128 Effective Date:

April 1, 2023

Q5128 Termination Date:

HCPCS Active

Cimerli billing and coding information can be found through Coherus Biosciences at the link below:
Cimerli patient assistance information can be found through Cimerli Solutions at the URL: https://www.cimerli.com/support/
Cimerli prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for Cimerli. Please check back in a few weeks.